Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Bieber

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1995
Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigensM E Esposito-Farese, C Sautès, H de la Salle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1994
Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cellsA Astier, H de la Salle, C de la Salle, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trialJ I Silverberg, D Toth, T Bieber, et al.
Allergy|December 24, 2009
Analysis of the high affinity IgE receptor genes reveals epistatic effects of FCER1A variants on eczema riskJ M Mahachie John, H Baurecht, E Rodríguez, et al.
Allergy|June 19, 2007
Putative association of a TLR9 promoter polymorphism with atopic eczemaN Novak, C-F Yu, C Bussmann, et al.
Human Gene Therapy|February 15, 2001
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trialB Wittig, A Märten, T Dorbic, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2012
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticariaM Magerl, M Rother, T Bieber, et al.
Allergy|March 18, 2017
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statementP W Hellings, W J Fokkens, C Bachert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1995
Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigensM E Esposito-Farese, C Sautès, H de la Salle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1994
Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cellsA Astier, H de la Salle, C de la Salle, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trialJ I Silverberg, D Toth, T Bieber, et al.
Allergy|December 24, 2009
Analysis of the high affinity IgE receptor genes reveals epistatic effects of FCER1A variants on eczema riskJ M Mahachie John, H Baurecht, E Rodríguez, et al.
Allergy|June 19, 2007
Putative association of a TLR9 promoter polymorphism with atopic eczemaN Novak, C-F Yu, C Bussmann, et al.
Human Gene Therapy|February 15, 2001
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trialB Wittig, A Märten, T Dorbic, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2012
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticariaM Magerl, M Rother, T Bieber, et al.
Allergy|March 18, 2017
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statementP W Hellings, W J Fokkens, C Bachert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trialsT Bieber, J P Thyssen, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
Pageof 20